Skyrizi was the top Rx and over-the-counter (OTC) pharma brand advertising on TV in 2024, according to data released by iSpot.tv on Thursday afternoon. AbbVie’s psoriasis, ulcerative colitis, Crohn’s ...

AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April, according to data released by iSpot.tv on Wednesday afternoon. The psoriasis treatment garnered an impressions ...

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way last month. | After spending much of the year sloping steadily downward from ...

AbbVie is once again the top spender on pharma TV ads, narrowly beating April's winner, Rexulti. That’s according to the latest data from real-time TV ad trackers at iSpot.TV, who crunched May’s ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, ...

Skyrizi (risankizumab-rzaa) is a prescription drug used to treat certain autoimmune conditions, including plaque psoriasis and Crohn’s disease. It works by attaching to specific proteins in your ...

AbbVie has received good news from the European Medicines Agency for a new use of its anti-inflammation drug Skyrizi, one of the best-selling products in its portfolio, now that blockbuster drug ...

Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...

Compared with placebo, a greater proportion of patients treated with Skyrizi achieved clinical remission in both the induction and maintenance trials. The Food and Drug Administration (FDA) has ...

Please provide your email address to receive an email when new articles are posted on . Patients who achieved endoscopic response or remission after induction had significantly fewer hospitalizations ...

AbbVie ABBV expects to return to robust revenue growth in 2025, just two years after losing U.S. exclusivity for its flagship drug, Humira. The drug, which went off-patent in January 2023, saw ...

Drug maker AbbVie Inc. on Tuesday said the Food and Drug Administration had approved its drug Skyrizi for adults with moderate to severe forms of ulcerative colitis, broadening the company’s arsenal ...